The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 3, 2011, Pages 366-377

  Dabholkar, A H ^a   Han, C ^a   Paris, M M ^a   Perez, M C ^a   Atkinson, S N ^a   Peura, D A ^b  

^a Research and Development   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATTAPULGITE; LANSOPRAZOLE; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CONNECTIVE TISSUE DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL PAIN; GOOD CLINICAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650871536     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04519.x     Document Type: Article

References (38)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R,. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. DeVault KR, Castell DO,. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
3. Bixquert M,. Maintenance therapy in gastro-oesophageal reflux disease. Drugs 2005; 65 (Suppl. 1): 59-66.
4. Donnellan D, Sharma N, Preston C, Moayyedi P,. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2: CD003245.
5. Freston JW, Hisada M, Peura DA, et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29: 1249-60.
6. Kovacs TO, Freston JW, Haber MM, Hunt B, Atkinson S, Peura DA,. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. Dig Dis Sci 2009; 54: 1693-701.
7. Hirschowitz BI, Mohnen J, Shaw S,. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 507-22.
8. Hirschowitz BI, Simmons J, Mohnen J,. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001; 15: 1795-806.
9. Hirschowitz BI, Simmons J, Mohnen J,. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3: 39-48.
10. Katsuki H, Yagi H, Arimori K, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 1996; 13: 611-5.
11. Zhang W, Wu J, Atkinson SN,. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology 2007; 132 (Suppl. 52): A487.
12. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive esophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from 2 randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 731-41.
13. Metz DC, Howden CW, Perez MC, Larsen LM, O'Neil J, Atkinson SN,. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29: 742-54.
14. Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN,. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis-maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009; 30: 895-907.
15. ICH Harmonised Tripartite Guideline. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. Available at:.
16. de la Loge C, Trudeau E, Marquis P, et al. Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res 2004; 13: 1751-62.
17. de La Loge C, Trudeau E, Marquis P, et al. Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol 2004; 2: 778-86. (Pubitemid 39200716)
18. Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res 2004; 13: 1737-49.
19. Revicki DA, Rentz AM, Tack J, et al. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol 2004; 2: 769-77. (Pubitemid 39200715)
20. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998; 158: 2373-6.
21. Kapidexâ¢. Dexlansoprazole. Deerfield, IL, USA: Takeda Pharmaceuticals America, Inc., 2009.
22. Freston JW, Rose PA, Heller CA, Haber M, Jennings D,. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf 1999; 20: 195-205.
23. Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN,. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther 2009; 30: 1010-21.
24. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE,. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009; 18: 269-75.
25. Metz DC, Bochenek WJ,. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 2003; 17: 155-64.
26. Robinson M, Lanza F, Avner D, Haber M,. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 859-67.
27. Adamek RJ, Behrendt J, Wenzel C,. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Eur J Gastroenterol Hepatol 2001; 13: 811-7.
28. Bonapace ES, Fisher RS, Parkman HP,. Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors? Dig Dis Sci 2000; 45: 34-9.
29. Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P,. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001; 24: 625-35.
30. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH,. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68.
31. Peura DA, Haber MM, Hunt B, Atkinson S,. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. J Clin Gastroenterol 2010; 44: 180-5.
32. Haber MM, Hunt B, Freston JW, et al. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment Pharmacol Ther 2010; 32: 83-96.
33. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB,. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006; 4: 852-9.
34. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34.
35. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22: 803-11.
36. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41. (Pubitemid 36259395)
37. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
38. Van Rensburg CJ, Honiball PJ, Van Zyl JH, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Aliment Pharmacol Ther 1999; 13: 1023-8.